Riley Antony A, CFO, reported a transaction classified as withholding at Forte Biosciences, Inc. involving 154.000000 shares for an estimated $3497.34. Reported holdings after the transaction were 30997.000000 shares. A 10b5-1 reference was not detected in the stored filing text.
Stored Form 4 columns with their raw values
Badges describe filing facts only — not predictions.
Compact filing score computed from stored Form 4 facts. Version v1.
This filing has a negative filing-only score. It may be less informative as an insider-activity signal and needs extra context.
Form 4 relationship flags and nearby filing context
CHIEF FINANCIAL OFFICER
Each restricted stock unit ("RSU") represents a contingent right to receive one share of Forte Biosciences, Inc. (the "Issuer") Common Stock.
On January 1, 2025, the Reporting Person's RSUs vested. The closing price of the Issuer's Common Stock on December 31, 2024 was the settlement price used to calculate the shares withheld.
Subject to the Reporting Person continuing to be a Service Provider (as defined in the 2021 Equity Incentive Plan) through each applicable vesting date, one-sixteenth (1/16th) of the RSUs subject to t…
0 other filings
0 recent txs